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answers. A clustered multivariate regression analysis explored theoretical validity of 
results. RESULTS: On average, respondents are willing to pay a12,920 (VAS scores) 
and a24,549 for a QALY (EuroQoL tariffs). Subgroup analysis showed great variation 
in WTP/QALY between income groups—from a5,000 in the lowest to a87,000 for a 
QALY in the highest group. Respondents that indicated a high level of certainty 
exhibited marginally higher WTP. Regression analyses showed a consistent relation-
ship between income, other demographics and WTP/QALY. CONCLUSIONS: Indi-
vidual WTP/QALY should be seen as a step to a sound empirical value of the social 
cost-effectiveness threshold in the Netherlands. Estimates elicited in this study are 
similar to those found in other empirical studies and are systematically lower than 
often cited thresholds, largely unsupported by empirical evidence (i.e. $50,000). 
However, there is a wide gap between the social and private value of a QALY. Future 
research should move towards estimating the social value of the cost-effectiveness 
threshold and align with the perspective of decision-makers thus creating a truly valu-
able decision-making tool.
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TECHNOLOGY: CLINICAL AND ECONOMICAL GAINS OF POINT-OF-
CARE APPLICATIONS FOR MEASURING POTASSIUM 
CONCENTRATIONS
Wetering G, Hummel JM, Montfort A, IJzerman MJ
University of Twente, Enschede, The Netherlands
OBJECTIVES: Innovative point-of-care diagnostics are likely to be having a strong 
impact on health care. The aim of this study is to conduct an early assessment of            
point-of-care chips. These chips can detect many particles and, consequently, many 
product-market combinations can be developed. This study investigates the impact of 
potential point-of-care applications in health care and to quantify the impact in terms 
of their likely cost-effectiveness. METHODS: The Analytic Hierarchy Process (AHP); 
a technique for multi-criteria analysis, and Markov modeling were applied in this early 
assessment. The AHP was used to prioritize six potentially attractive product-market 
combinations (PCM’s). For estimating the future cost-effectiveness of the most attrac-
tive PMC’s, Markov health state transition models were developed. Two Markov 
models were constructed; models for a potassium chip for both stage 5 CKD patients 
as well as heart failure (HF) patients which suffer from edemas. RESULTS: AHP 
identiﬁed clinical gain as being the most important criterion to assess the attractiveness 
of a PMC, followed by market potential, attitude of professionals, R&D barriers and 
implementation barriers. Regarding these criteria, a potassium-chip for Chronic 
Kidney Disease (CKD) and Heart Failure (HF) patients was calculated to be the most 
attractive alternative. Markov model cohort simulation yielded incremental cost-effec-
tiveness ratios (ICERs). The point-of-care chip appeared not to be cost-effective for 
preventing hyperkalemia in stage 5 CKD patients. For HF patients suffering from 
edemas the chip was estimated to be cost-effective and could provide a valuable asset 
to current treatment. CONCLUSIONS: The AHP is valuable in supporting the iden-
tiﬁcation of potentially attractive product-market combinations. For the best combina-
tions, Markov modeling can subsequently provide a more in-depth analysis of the 
future cost-effectiveness.
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OBJECTIVES: At present the costs and effects of providing informal care are often 
ignored in economic evaluations. This is problematic since considering informal      
care a ‘zero cost’ substitute for formal care may result in non-optimal decisions from      
a societal perspective, at the burden of carers. This study further investigates 
the validity of the CarerQol instrument, which values the full impact of informal 
care on caregivers. The CarerQoL consists of seven burden dimensions (CarerQol-7D)      
and a visual analogue scale measuring happiness (CarerQol-VAS). METHODS: 
A questionnaire was distributed by mail among a sample of caregivers (n  1100) 
via regional support centres for informal caregivers throughout the Netherlands. 
Construct validity (n  249) was tested with Spearman’s correlation coefﬁcients of        
the CarerQol-VAS and the CarerQol-7D and two measures of subjective burden 
and the utility of care giving. Clinical validity was evaluated by the multivariate cor-   
relation between the CarerQol-VAS and characteristics of the caregiver, care recipient 
and care situation. Differences in CarerQol-VAS scores among caregivers are explained 
with subgroup multiple linear regression analyses and principal component analyses. 
RESULTS: CarerQol-VAS scores were negatively associated with burden and posi-
tively with utility of caring. The seven dimensions of the CarerQol-7D were also 
associated with burden and utility of caring in the expected direction, for six dimen- 
sions the associations were statistically signiﬁcantly. Signiﬁcant associations with 
CarerQol-VAS scores were found for a range of characteristics, including duration 
and intensity of care, relationship between carer and patient, carer education level and 
patient age. CONCLUSIONS: Our results further support the construct and clinical 
validity of the CarerQol and thus underlines the relevance of this instrument 
for including informal care effects in economic evaluations. The next, necessary 
step in the development of the CarerQol concerns the establishment of tariffs for the             
caring situations deﬁned by the seven dimensions. This is the topic of coming           
research.
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OBJECTIVES: To assess the provision of health care and reimbursement in ambula-
tory palliative care in Germany. METHODS: A survey was conducted among 1000 
ofﬁce-based physicians in January 2009, covering e.g. the following topics: quantity 
of palliative care, its reimbursement and resource use due to side effects of opioid 
medication. RESULTS: A total of 314 physicians (30% response rate) were included 
in the statistical analysis. A total of 63.7% were general practitioners (GP), 36.3% 
specialists. A total of 67% of all physicians were additionally trained in palliative 
medicine. Fifty percent estimate efforts associated with palliative care to be at least 
1.5 times higher compared to patients with other serious conditions. On average GPs 
(specialists) visit palliative patients 5.9 (3.7) times per quarter at home (2.3 (1.2) visits 
for non-palliative though sick patients, p  0.01). Overall palliative patients also 
require more ofﬁce consultations compared to nonpalliative patients (4.6 vs. 3.5, GP 
4.7 vs. 3.5, specialist 4.5 vs. 3.4, all p  0.01) and need more time per visit (17.5 min 
versus 11.5 min) (p  0.01). Constipation is the most frequent side-effect in opioid 
medication and requires app. 20% more time and effort compared to no constipation. 
According to the German Remuneration Scheme (EBM) GPs (specialists) receive a 
lump-sum per quarter for ofﬁce consultations, irrespective of number or length of visit 
or palliative status, of app. a35 (31) and a mean of app. a7.50 (7) for a basic consulta-
tion. Hence, 95% (60%) of the participants trained in palliative care evaluate the 
reimbursement and health care structures in the German setting as insufﬁcient or very 
insufﬁcient. CONCLUSIONS: Compared to non-palliative there is a higher need for 
medical resources among palliative patients—a need that is currently not reﬂected in 
the remuneration system. Considering the demographic development and the resulting 
signiﬁcance of palliative care further research should focus on identifying room for 
improvement and corresponding strategies.
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OBJECTIVES: To assess the prescription drug knowledge and the impact of counsel-
ing on it in patients visiting a public teaching hospital. METHODS: A standardized 
questionnaire of prescription drug knowledge that embraces 8 questions e.g. drug 
name, indication, side effect, dose, frequency of dosing, dosage schedule, storage and 
missed dose action of prescription drugs was used. Education level was set as group-1 
illiterate patients, group-2 education up to secondary school and group-3 graduate 
patients. The patients were scored 1 for every correct answer, with a maximum of 8. 
The overall scores were then categorized as low (3), medium (3–6) and high (6). 
Patients were counseled by oral, written, oral-pictorial combine, written-pictorial 
combine and oral-written-pictorial combine for all the questions. Post counseling 
evaluation was performed to assess the impact of patient counseling. RESULTS: Total 
753 patients were assessed. Patient’s knowledge about prescription drug name, side 
effect, dose and missed dose action was poor. The prescription drug knowledge score 
was low (3) in group-1 and the patients of acute drug treatment. Whereas, medium 
(3–6) knowledge score was observed in group-2, group-3 and patients of chronic drug 
treatment. The overall score was improved from 3.43 o 1.47 to 6.20   o 1.26 after  
counseling in all enrolled patients. After counseling overall score was improved from 
2.88 o 1.40 to 6.01   o 1.16 and from 3.71    o 1.43 to 6.30   o 1.29 in patients of acute     
and chronic drug treatment, successively. Improvement in overall score was observed 
from 2.78 o 1.37 to 5.55   o 1.19, from 3.52   o 1.10 to 6.32   o 0.88 and from 4.49    o 
1.55 to 7.25 o 1.17 in educational group-1, group-2 and group-3 after counseling,         
respectively. CONCLUSIONS: Patients having low level of education, acute drug 
treatment and especially female patients know little about their prescribed drugs. 
Patient counseling about their prescribed drugs will help to improve the patient’s 
compliance and may lead to achieve better patient outcome.
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OBJECTIVES: The purpose of the current study is to evaluate the pharmaceutical 
industries’ situation and the effective factors in pharmaceutical products exportation 
in successful exporting countries and to compare the results with the situation of 
pharmaceutical industries in Iran and the factors affecting their exportation experi-
ences. METHODS: For the purposes of current cross-sectional study, an analytic 
questionnaire with open ended questions was designed which consisted of 32 questions 
in 8 ﬁelds. Subjects of the study consisted of 20 experts and ofﬁceholders of pharma-
ceutical industries and pharmaceutical products exporting companies and relevant 
governmental sections. Relevant information regarding pharmaceutical industries and 
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exportation of pharmaceutical products by target countries has also been gathered 
through library and the Internet researches. RESULTS: The result of study regarding 
rate of export showed an increasing rate (each year growth) of 20%, (from 1348 to 
2881 million $), 18% (from 1978 to 3777 million $), 10% (from 193 to 295 million 
$) for India, China and Jordan respectively as developing countries during 2001–2005 
and 44% (from 2435, 6722 million $), 40% (from 1450 to 3483 million $) for Spain 
and Canada in the same period of time as developed countries. Iran’s pharmaceutical 
export reached to 66.4 from 13 million $ in the same period. CONCLUSIONS: While 
Iran has not experienced a successful exporting situation at the same period of time 
India, Jordan, Spain and Canada have taken successful steps in the ﬁeld of exportation 
during recent years by implementing desirable exports expanding policies; it seems 
that disharmonies and lack of a desirable policy and insufﬁciencies of applied proce-
dures are responsible for mentioned situation of Iran.
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OBJECTIVES: The appropriate and accurate classiﬁcation of outpatient infusion ser-
vices is a strategic hospital responsibility having widespread operational impact. Site 
of care designation, speciﬁcally whether a service setting is provider-based or non-
provider-based, determines the mechanism of Medicare payment and dictates the 
program structure required for operational compliance. This project was designed 
to review models of hospital outpatient drug administration services; discuss the 
Medicare reimbursement implications, and illustrate options for hospital planning. 
METHODS: The history and evolution of provider-based criteria was arrayed along 
a timeline and the relevant regulations and legislation cited. The provider-based deﬁni-
tions and criteria were described and the concept of “incident-to the physician’s ser-
vices” was explored as a Medicare requirement. Provider and non-provider models 
were compared and contrasted for the following characteristics: functional appearance 
and processes; Medicare billing and payment, and patient ﬁnancial responsibilities. 
Hospital strategic choices were reviewed. RESULTS: There are two primary model 
options for hospital outpatient infusion service delivery: provider-based and non-
 provider-based. The provider-based model allows infusion services to operate as a 
hospital department and to bill and receive payment from Medicare under the outpa-
tient prospective payment system, as long as the regulatory deﬁnitions and criteria 
are met. Non-provider-based infusion services operate as a medical practice model, 
allowing the hospital to bill and receive payment from Medicare under the physician 
fee schedule. CONCLUSIONS: Hospitals choosing to offer infusion services may do 
so via either model. Each has unique implications for Medicare reimbursement, 
hospital operations and beneﬁciary ﬁnancial responsibility. With informed know- 
ledge of the options, hospital decision-makers are better prepared to position infusion 
programs appropriately within the context of their facility’s mission and 
capabilities.
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OBJECTIVES: In the Netherlands, orphan drug developers can be exempted from 
providing a full pharmacoeconomic evaluation when applying for reimbursement,      
whereas in Scotland no such exceptions can be made. METHODS: All orphan drug 
reimbursement reports from the Dutch reimbursement institution (CFH) and guidance 
issued by the Scottish Medicines Consortium (SMC) were collected.    RESULTS: 38 
orphan drugs were submitted to the CFH; 37 to the SMC. Only one CFH submission 
included a full pharmacoeconomic evaluation, while almost all SMC submissions did. 
The CFH gave positive recommendations for reimbursement for 36 submissions    
(95%). In contrast, of the 37 SMC submissions, 19 (51%) received a positive recom-
mendation for use. Half of the SMC submissions reported an unfavourable cost-
 effectiveness outcome; almost all of these received a negative recommendation. 
CONCLUSIONS: Differences in policies and requirements for submissions for orphan 
drugs can explain discrepancies in reimbursement and guidance for use decisions 
between Scotland and the Netherlands.
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OBJECTIVES: Since 2005 it is obligatory in the Netherlands to submit pharmaco-
economic evidence for innovative drugs. The aim of our study is to describe the role 
of pharmacoeconomics in decision-making in the Dutch reimbursement system. 
METHODS: We used the analytical Hutton framework for assessing ‘fourth-hurdle’ 
systems to analyse the Dutch drug reimbursement system. We examined policy docu-        
ments, explored literature and conducted interviews with policy makers and represen-
tatives of the pharmaceutical industry. RESULTS: Different schemes exist for inpatient 
and outpatient drugs. Expensive hospital drugs obtain positive decisions without 
extensive pharmacoeconomic evidence. After a period of three years, it is required to 
submit evidence on real-world cost-effectiveness. However, the ﬁrst reassessments are      
yet to be conducted. In contrast, innovative outpatient drugs are only reimbursed after 
an assessment of pharmacoeconomic evidence. The Dutch Health Care Insurance 
Board and the Pharmaceutical Advisory Committee advise the minister on the robust-
ness of cost-effectiveness evidence, whereas the latter takes the ﬁnal decision. Recently, 
assessment and appraisal have become two separate phases in decision-making. The 
impact of the appraisal committee is still unclear. The near future will show if they 
take the lead on advising on value for money. No party has taken up this role until 
now, only the Council for Public Health and Healthcare suggested a threshold range. 
The industry, however, anticipates that the new committee just adds another hurdle. 
CONCLUSIONS: The importance of pharmacoeconomics has increased in Dutch 
drug reimbursement decision-making, but plays an uncertain role. It seems that the 
‘fourth-hurdle’ system is more lenient towards expensive inpatient and orphan drugs. 
In future research we focus on investigating reimbursement dossiers to reveal implicit        
and explicit decision criteria. Furthermore, we aim to research reimbursement systems 
within several European countries to obtain insight into best practice systems that 
deliver value for money.
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OBJECTIVES: The mature health economies as exampled by the G7 Countries have 
developed collectively a plethora of supply and demand side controls to control access 
to medicines. Health Policy makers, Payers and Health insurance bodies are expected 
to utilize new P & R tools to ensure value for money. A survey was undertaken 
amongst health policy experts to understand trends in P & R Policy reform. 
METHODS: Over 2008/9 23 health policy experts were interviewed from 7 health 
economies. Speciﬁc examples of new and emerging policy reforms were sought with 
insights requested into how the market access landscape is likely to be transformed 
over the next decade. P & R tools were classiﬁed using the well recognized nomen-
clature of supply and demand side controls. RESULTS: There is harmonization of 
thinking amongst health policy leads that unregulated access to medicines is not a 
tenable or sustainable option. The EU has a long established group of P & R policy 
tools to choose from. New initiatives such as ﬂexible pricing and innovative patient 
access schemes are becoming more prevalent. In the US an absence of supply side-side 
initiatives at a Government level leave individual States to negotiate on Medicare 
programmes. New policy initiatives emerging include a focus on cost-effectiveness and 
health economics to prioritise drug spend. CONCLUSIONS: The EU markets have to 
date led the way in developing innovative P & R tools, but even within these markets, 
tools have had various degree of success in terms of overall cost containment. 
However, the US demonstrated to be the most dynamic health care system likely to 
undergo policy reforms in the near future led by the American Rescue and Recovery 
Act (ARRA). Although there are clear differences, the recently announced changes 
may result in a closer resemblance between the US and EU P & R markets.
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OBJECTIVES: A fundamental assumption of Medicare’s rate setting methodology for 
Speciﬁed Covered Outpatient Drugs (SCODs) is that pharmacy overhead and handling 
costs are included by hospitals in their drug charges. Provider reported data does not 
consistently support that assumption. This study explores the history and current 
status of this debate and presents additional evidence of the continued variability in 
hospital drug charge composition and reporting. METHODS: Preparation input 
included review of legislation and Medicare regulations relevant to outpatient drug 
payment and pharmacy overhead. Historic discussions of pharmacy costs and charges 
were identiﬁed and accumulated in an indexed database. Data regarding the nature 
of hospital drug charges were collected from a 2008 hospital survey (n  356). 
RESULTS: Historic analyses of Medicare’s rate setting methodology for SCODs 
support the hypothesis that hospitals may be underpaid for these products, due in part 
to underestimation of the related costs for pharmacy handling and services. Medicare’s 
methodology relies upon hospital reported charges submitted on the cost report. The 
hospital survey revealed that 40% of the respondents do not include in their drug 
charges amounts for anything beyond drug acquisition cost. CONCLUSIONS: Medi-
care’s outpatient drug payment rates continue to be derived from hospital charges 
which have demonstrated wide variability in recognizing pharmacy overhead costs. 
Although there have been recurring recommendations to Medicare for rate setting 
methodologies that can adequately address drug handling as well as acquisition costs, 
outpatient hospital drug reimbursement has now declined for two consecutive years. 
Failure to resolve this issue may threaten the ability of hospital providers to continue 
to offer outpatient drug services.
